Voyager Therapeutics Inc
VYGR
Get informed when a big investor buys or sells
+ FollowMarket Cap$186.7M
Close$
$-3.04
196.9% downside
Current Fair Value
196.9% downsideOvervalued by 196.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $186.70 Million |
|---|---|
| Enterprise Value | $183.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.04 |
| Beta | 1.32 |
| Outstanding Shares | 60,547,863 |
Return
| Return on Equity | -69.78% |
|---|---|
| Return on Assets | -54.48% |
| Return on Invested Capital | -46.93% |
Valuation & Multiples
| P/E Ratio | -1.71 |
|---|---|
| PEG | 6.4 |
| Price to Sales | - |
| Price to Book Ratio | 1.57 |
| Enterprise Value to Revenue | 5.33 |
| Enterprise Value to EBIT | -2.16 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.21 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$4.52 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.41
Average shareholder expectationRevenue Estimate
$6.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0315▼ 24.79% |
|---|---|
| Total Calls | 466,279▲ 166.48% |
| Total Puts | 14,700▼ 69.94% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 58.15%▲ 1.81% |
|---|---|
| Total Invested | $123.29M▼ 4.72% |
| Investors Holding | 144▲ 5.00% |
ESG Score
No data
About Voyager Therapeutics Inc
CEO: G. Andre Turenne